Literature DB >> 10025736

Measurement of four tumor marker antigens in the sera of pregnant women.

C D Cheli1, D L Morris, I E Neaman, J Dai, W J Allard, K K Yeung.   

Abstract

We sought to determine the maternal serum levels of four tumor-associated antigens during the three trimesters of pregnancy in healthy women. CEA, CA 228, CA 15-3, and Her2/neu oncogene product p105 assay values were determined for 90 healthy pregnant women during the three trimesters of pregnancy at five participating evaluation sites. Results were compared to means and cut-off values determined for healthy nonpregnant women. Differences in assay values in the 1st and 3rd trimester were analyzed for statistical significance (Student's t-test). CEA, CA 228 and CA 15-3 assay values in general were found to be within the normal range. CA 15-3 and Her2/neu p105 serum assay values were above the cut-off (3.3% and 8.2%, respectively) and were significantly elevated in the 3rd trimester as compared to the 1st trimester of pregnancy (P < 0.05 and P < 0.001, respectively). CEA and CA 228 may be of potential value in monitoring pregnant women with malignant disease. Normal elevations in 3rd trimester serum Her2/neu p105 and CA 15-3 assay values should be considered when monitoring a pregnant patient with malignant disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025736      PMCID: PMC6807807     

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  18 in total

1.  Adjuvant chemotherapy for breast cancer in pregnancy: can recommendations be made with confidence.

Authors:  J Stevenson; B Giantonio; R L Boyd; J A Bruner
Journal:  Semin Oncol       Date:  1997-04       Impact factor: 4.929

2.  Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.

Authors:  D F Hayes; V R Zurawski; D W Kufe
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

3.  Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid.

Authors:  R J Lellé; E Henkel; D Leinemann; K Goeschen
Journal:  Gynecol Obstet Invest       Date:  1989       Impact factor: 2.031

Review 4.  Cancer in pregnancy: a review of the literature. Part I.

Authors:  N M Antonelli; D J Dotters; V L Katz; J A Kuller
Journal:  Obstet Gynecol Surv       Date:  1996-02       Impact factor: 2.347

5.  Tumor markers in hypertensive disorders of pregnancy.

Authors:  H Schröcksnadel; G Daxenbichler; E Artner; G Steckel-Berger; O Dapunt
Journal:  Gynecol Obstet Invest       Date:  1993       Impact factor: 2.031

6.  Serum tumor markers for patient monitoring: a case-oriented approach illustrated with carcinoembryonic antigen.

Authors:  H A Fritsche
Journal:  Clin Chem       Date:  1993-11       Impact factor: 8.327

7.  Measurement of Tennessee antigen, carcinoembryonic antigen, tissue polypeptide antigen and alpha-feto-protein in body fluids associated with pregnancy.

Authors:  P Oehr; O Bellmann; D Hamann
Journal:  Clin Biochem       Date:  1982-02       Impact factor: 3.281

8.  Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer.

Authors:  W J Allard; I E Neaman; J J Elting; T R Barnett; H Yoshimura; H A Fritsche; K K Yeung
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

9.  Overexpression of her-2/neu in human prostate cancer and benign hyperplasia.

Authors:  K Gu; A M Mes-Masson; J Gauthier; F Saad
Journal:  Cancer Lett       Date:  1996-02-06       Impact factor: 8.679

10.  Behaviour of four serum tumor markers in pregnant women.

Authors:  M Correale; I Abbate; C D Dragone; T Tedone; M D Musci; G Gargano; A M Catino; A M Bafunno; B Grossi
Journal:  Int J Biol Markers       Date:  1993 Jul-Sep       Impact factor: 3.248

View more
  6 in total

1.  Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women.

Authors:  Jie Lu; Zhipeng Zheng; Qi Zhang; Guoli Li; Fengying Li; Zhian Le; Jun Huang; Xinyou Xie; Jun Zhang
Journal:  J Clin Lab Anal       Date:  2017-11-30       Impact factor: 2.352

2.  Primary strumal carcinoid tumor of the ovary: A pregnant patient exhibiting severe constipation and CEA elevation.

Authors:  Munekage Yamaguchi; Hironori Tashiro; Ken-Ichi Motohara; Takashi Ohba; Hidetaka Katabuchi
Journal:  Gynecol Oncol Case Rep       Date:  2012-11-17

3.  Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review.

Authors:  Sileny N Han; Anouk Lotgerink; Mina Mhallem Gziri; Kristel Van Calsteren; Myriam Hanssens; Frédéric Amant
Journal:  BMC Med       Date:  2012-08-08       Impact factor: 8.775

4.  Evaluation of the UniCel™ DxI 800 immunoassay analyzer in measuring five tumor markers.

Authors:  Younhee Park; Yongjung Park; Jungyong Park; Hyon-Suk Kim
Journal:  Yonsei Med J       Date:  2012-05       Impact factor: 2.759

5.  Can we trust tumour markers in pregnancy after breast cancer? A case of elevated CA 15-3 in the third trimester of pregnancy normalising after delivery.

Authors:  Barbara Buonomo; Stefania A Noli; Alessandra Santini; Carlo Alviggi; Fedro A Peccatori
Journal:  Ecancermedicalscience       Date:  2019-11-26

Review 6.  The relationship between early embryo development and tumourigenesis.

Authors:  Yanlei Ma; Peng Zhang; Feng Wang; Jianjun Yang; Zhe Yang; Huanlong Qin
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.